Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.
BACKGROUND
The cellular immune responses that protect against tuberculosis have not been identified.


METHODS
We assessed baseline interferon γ (IFN‐γ) and lymphocyte proliferation assay (LPA) responses to antigen 85 (Ag85), early secretory antigenic target 6 (ESAT‐6), and Mycobacterium tuberculosis whole cell lysate (WCL) in human immunodeficiency virus (HIV)-infected and bacille Calmette‐Guérin (BCG)-immunized adults with CD4 cell counts of >or= 200 cells/μL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania. Subjects were followed prospectively to diagnose definite or probable tuberculosis.


RESULTS
Tuberculosis was diagnosed in 92 of 979 subjects during a mean follow‐up of 3.2 years. The relative risk of tuberculosis among subjects with positive IFN‐γ responses to Ag85 was 0.51 (95% confidence interval [CI], 0.26-0.99; P = .049), to ESAT‐6 was 0.44 (95% CI, 0.23-0.85; P = .004), and to WCL was 0.67 (95% CI, 0.49-0.88; P = .002). The relative risk of tuberculosis was not significantly associated with baseline LPA responses. In a multivariate Cox regression model, subjects with IFN‐γ responses to ESAT‐6 and WCL had a lower hazard of developing tuberculosis, with a hazard ratio for ESAT‐6 of 0.35 (95% CI, 0.16–0.77; P = .009) and a hazard ratio for WCL of 0.30 (95% CI, 0.16-0.56; P < .001).


CONCLUSIONS
Baseline IFN‐γ responses to ESAT-6 and WCL were associated with protection from subsequent tuberculosis among HIV-infected subjects with childhood BCG immunization in a region of high tuberculosis prevalence. Trial registration. ClinicalTrials.gov identifier: NCT00052195.
Lahey
Timothy
T
Dartmouth Medical School, Lebanon, New Hampshire, USA.
Sheth
Siddharth
S
Matee
Mecky
M
Arbeit
Robert
R
Horsburgh
C Robert
CR
Mtei
Lillian
L
Mackenzie
Todd
T
Bakari
Muhammad
M
Vuola
Jenni M
JM
Pallangyo
Kisali
K
von Reyn
C Fordham
CF
D000328:Adult; D000942:Antigens, Bacterial / Q000276:immunology*; D001500:BCG Vaccine / Q000276:immunology; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology*; D008297:Male; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D012307:Risk Factors; D013636:Tanzania; D014376:Tuberculosis / Q000150:complications* / Q000276:immunology*
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D007371:Interferon-gamma
Clin Infect Dis. 2000 Jun;30 Suppl 3:S309-15
10875806
Lancet. 2006 Mar 18;367(9514):938-40
16546542
N Engl J Med. 1999 Feb 4;340(5):367-73
9929528
AIDS. 2006 Apr 4;20(6):821-9
16549965
Am J Respir Crit Care Med. 2006 Jan 1;173(1):133-4; author reply 134-5
16368796
Int J Tuberc Lung Dis. 1999 Mar;3(3):239-47
10094326
Trop Med Int Health. 2007 Jun;12(6):700-8
17550467
JAMA. 1994 Mar 2;271(9):698-702
8309034
N Engl J Med. 1996 Dec 26;335(26):1956-61
8960475
BMC Infect Dis. 2009 Feb 23;9:21
19236695
J Infect Dis. 2007 Jan 1;195(1):118-23
17152015
AIDS. 2003 Nov 7;17(16):2351-5
14571187
Int J Infect Dis. 2005 Mar;9(2):110-6
15708327
Am J Respir Crit Care Med. 2009 Oct 1;180(7):674-83
19628776
Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41
18713501
J Infect Dis. 2005 Aug 1;192(3):480-7
15995962
N Engl J Med. 1997 Sep 18;337(12):801-8
9295239
Ann N Y Acad Sci. 1968 Sep 5;154(1):140-8
5266317
Ann Intern Med. 2008 Aug 5;149(3):177-84
18593687
J Infect Dis. 2008 Apr 1;197(7):990-9
18419535
J Infect Dis. 1996 Jul;174(1):113-9
8655980
Lancet. 2008 Jul 12;372(9633):164-75
18620952
J Infect Dis. 1998 Jul;178(1):138-46
9652433
J Clin Microbiol. 2001 Mar;39(3):1042-7
11230425
Clin Infect Dis. 2009 Apr 1;48(7):954-62
19245343
Ann Intern Med. 2008 Dec 2;149(11):777-87
18936496
Clin Infect Dis. 2005 May 15;40(10):1500-7
15844073
Microbes Infect. 2005 Jul;7(9-10):1161-9
15908253
Lancet. 1995 Nov 18;346(8986):1339-45
7475776
Am J Respir Crit Care Med. 2004 Jul 1;170(1):59-64
15059788
Lancet. 2002 Apr 20;359(9315):1393-401
11978337
Clin Exp Immunol. 1997 Oct;110(1):26-34
9353145
J Immunol. 1999 Aug 15;163(4):2249-55
10438968
Clin Infect Dis. 2004 Mar 1;38(5):757-9
14986263
Int J Tuberc Lung Dis. 1999 Mar;3(3):255-60
10094328
Curr Opin Pulm Med. 2005 May;11(3):195-202
15818179
Pediatrics. 1995 Jul;96(1 Pt 1):29-35
7596718
Tubercle. 1985 Jun;66(2):121-8
4024270
Clin Infect Dis. 2007 Jun 15;44(12):1639-46
17516410
J Immunol. 1997 Feb 15;158(4):1949-55
9029137
BMC Infect Dis. 2007 Aug 28;7:99
17725839
Am J Respir Crit Care Med. 2008 May 15;177(10):1164-70
18276940
J Infect Dis. 1993 Dec;168(6):1553-8
8245545
Clin Infect Dis. 2004 Mar 1;38(5):754-6
14986262
Int J Tuberc Lung Dis. 2001 Dec;5(12):1122-8
11769770
J Immunol. 2008 Mar 1;180(5):3569-77
18292584